Cover Image
Market Research Report

Global Epigenetics Drugs & Diagnostic Technologies Market - 2019-2026

Published by DataM Intelligence Product code 879301
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Epigenetics Drugs & Diagnostic Technologies Market - 2019-2026
Published: June 1, 2019 Content info: 130-180 Pages
Description

Global Epigenetics Drugs & Diagnostic Technologies Market Overview

The global Epigenetics Drugs & Diagnostic Technologies market was worth US $ billion in 2018 and is forecasted to reach US$ billion by 2026, at a CAGR of % during the forecast period.

Epigenetics is a process of changing the gene expression; it's a phenotype change without a change in genotype. The essential parts that are engaged with epigenetic interpretation are DNA methylation, histone changes, and non-coding RNA's. Epigenetics drugs and diagnostic technologies are used in the screening of early-stage cancer and other abnormal changes in liver cells, brain cells, skin cells, and others. With the rising awareness among people and rising incidences & prevalence of oncology and non-oncology disorders, the interest for epigenetic analysis and medications is growing at a high pace and boosting the global epigenetics drugs and diagnostics technologies market.

Global Epigenetics Drugs & Diagnostic Technologies Market - Market Dynamics

Rising prevalence of cancer and other chronic diseases along with growing geriatric population are the major factors driving the global epigenetics drugs & diagnostic technologies market. According to WHO, in 2018, there are an estimation of 18.1 million new cancer cases and 9.6 million deaths, about 1 in 6 deaths are due to cancer. Thus, growing cancer incidences are boosting the market growth.

Also, funding's by government organizations such as the National Cancer Institute (NCI), the International Human Epigenome Consortium (IHEC), and the National Institute of Health (NIH) to promote R&D activities is anticipated to propel the global epigenetics drugs & diagnostics market further. Further, increased attention of manufacturers towards the development of new epigenetics drugs is boosting the market growth.

Global Epigenetics Drugs & Diagnostic Technologies Market - Segment Analysis

Based on product, the global Epigenetics Drugs & Diagnostic Technologies market is broadly segmented as oncology and non-oncology segment. Oncology application segment accounted for major market share in 2018, owing to the growing prevalence of cancer. However, over the forecast period, non-oncology application segment is expected to grow at a high pace. It is due to R&D initiatives undertaken by private institutions and biopharmaceutical companies for identification of epigenetic markers related to non-oncology disorders. Non-oncology disorders include cardiovascular, infectious, and other disorders. Epigenetic modifications have been proved to be the base of metabolic, infectious diseases, neurodegenerative, and many other non-oncology disorders. Thus, growing non-oncology disorder segment is driving the global market.

Global Epigenetics Drugs & Diagnostic Technologies Market - Geographical Analysis

The global Epigenetics Drugs & Diagnostic Technologies market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America region accounted for major market share in 2018, in the global epigenetics drugs & diagnostics technologies market. Presence of government funding programs for ongoing research activities, better healthcare facilities, and continuously increasing incidences of oncology and non-oncology diseases including metabolic, infectious, cardiovascular, and other diseases.

During the forecast period (2019-2026), the Asia Pacific region is projected to grow at a significant rate, owing to the rising disposable income, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China. Additionally, due to increasing cases of various types of cancers. Also, due to the presence of prominent players of the market, such as Eisai Pharmaceuticals and Oncolys Biopharma.

Global Epigenetics Drugs & Diagnostic Technologies Market - Competitive Analysis

Significant players of the global epigenetics drugs & diagnostic technologies market are Thermo Fisher Scientific., Merck & Company Inc., Novartis International AG, Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celeron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, Epigentek Group Inc., and others. The diversified product portfolio is the major factor that is responsible for strengthening the position of these companies in the market. Also, they have been adopting key strategies, such as new product developments, acquisitions, and expansions, to increase their share in the epigenetics drugs & diagnostics market. For instance, in

  • In January 2018, Thermo Fisher Scientific collaborated with Illumina, Inc. to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina's next-generation sequencing (NGS) platforms.
  • In August 2017, BellBrook Labs announced the launch of AptaFluor SAH Methyltransferase Assay, to help researchers in their research for breakthrough drugs targeting epigenetic pathways that drive cancer and other debilitating diseases.
  • In May 2017, Merck developed alternative genome editing tool that makes CRISPR more efficient, flexible, and specific.
  • In October 2015, Celgene's VIDAZA® was approved by the European Commission(EC).
  • In April 2015, Roche and Oryzon collaborated to develop and commercialize LSD1 inhibitors for oncology, and non-malignant conditions

Why Purchase the Report?

  • Visualize the composition of the Epigenetics Drugs & Diagnostic Technologies market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the Epigenetics Drugs & Diagnostic Technologies market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Epigenetics Drugs & Diagnostic Technologies market - level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1. Global Epigenetics Drugs & Diagnostic Technologies Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Epigenetics Drugs & Diagnostic Technologies Market - Market Definition and Overview

3. Global Epigenetics Drugs & Diagnostic Technologies Market - Executive Summary

  • 3.1. Market Snippet by Technology
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Global Epigenetics Drugs & Diagnostic Technologies Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of cancer and other chronic diseases
      • 4.1.1.2. Funding's by Government Organizations
    • 4.1.2. Restraints
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Epigenetics Drugs & Diagnostic Technologies Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis

6. Global Epigenetics Drugs & Diagnostic Technologies Market - By Technology

    • 6.1.1. Introduction
    • 6.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.3. Market Attractiveness Index, By Technology
  • 6.2. DNA Methylation
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 6.3. Chromatin Immunoprecipitation (ChIP) Technology
  • 6.4. Histone Methylation
  • 6.5. MicroRNA Modification
  • 6.6. Others

7. Global Epigenetics Drugs & Diagnostic Technologies Market - By Application

    • 7.1.1. Introduction
    • 7.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 7.1.3. Market Attractiveness Index, By Application
  • 7.2. Oncology
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.3. Non-Oncology
    • 7.3.1. Inflammatory Diseases
    • 7.3.2. Cardiovascular Diseases
    • 7.3.3. Infectious Diseases

8. Global Epigenetics Drugs & Diagnostic Technologies Market - By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. The U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. The U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Italy
      • 8.3.5.5. Spain
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia Pacific
  • 8.6. Middle East & Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

9. Global Epigenetics Drugs & Diagnostic Technologies Market - Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Competitor Epigenetics Drugs & Diagnostic Technologies Strategy Analysis
  • 9.3. Comparative Technology Portfolio Analysis
  • 9.4. Market Positioning/Share Analysis
  • 9.5. Mergers and Acquisitions Analysis

10. Global Epigenetics Drugs & Diagnostic Technologies Market - Company Profiles

  • 10.1. Thermo Fisher Scientific.
    • 10.1.1. Company Overview
    • 10.1.2. Technology Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. Merck & Company, Inc.
  • 10.3. Novartis International AG
  • 10.4. Astex Pharmaceuticals Inc.
  • 10.5. Celenge
  • 10.6. CellCentric Ltd.
  • 10.7. Celeron Therapeutics Ltd.
  • 10.8. Chroma Therapeutics Ltd.
  • 10.9. Eisai Pharmaceuticals
  • 10.10. Epigentek Group Inc

11. Global Epigenetics Drugs & Diagnostic Technologies Market - Premium Insights

12. Global Epigenetics Drugs & Diagnostic Technologies Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us
Back to Top